Standout Papers

Naringenin attenuates non‐alcoholic fatty liver disease by down‐regulating the NLRP3/NF‐κB pathway in mice... 2019 2026 2021 2023 220
  1. Naringenin attenuates non‐alcoholic fatty liver disease by down‐regulating the NLRP3/NF‐κB pathway in mice (2019)
    Qinyu Wang, Guomin Hu et al. British Journal of Pharmacology

Immediate Impact

1 by Nobel laureates 5 from Science/Nature 61 standout
Sub-graph 1 of 22

Citing Papers

The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout
Therapy-induced senescent cancer cells contribute to cancer progression by promoting ribophorin 1-dependent PD-L1 upregulation
2025 Standout
2 intermediate papers

Works of Lu Xu being referenced

E3 ubiquitin ligases Cbl‐b and c‐Cbl downregulate PD‐L1 in EGFR wild‐type non‐small cell lung cancer
2018
Tumor antigen-specific CD8+ T cells are negatively regulated by PD-1 and Tim-3 in human gastric cancer
2017

Author Peers

Author Last Decade Papers Cites
Lu Xu 305 424 301 44 1.0k
Rosa Divella 379 375 232 38 1.2k
Qingyan Liu 252 356 260 37 1.0k
Chao‐Wen Cheng 247 571 143 64 1.4k
Jingyun Luan 211 723 327 35 1.4k
Christelle Laguillier 250 370 264 33 1.3k
Eliana Guerriero 185 462 190 34 1.2k
Liping Meng 146 540 126 50 1.0k
Patrizia Bonelli 151 498 171 53 990
Evelyn SC Koay 217 413 151 36 965
Shinobu Miyazaki‐Anzai 289 430 291 30 1.3k

All Works

Loading papers...

Rankless by CCL
2026